Prescient Therapeutics
Prescient Therapeutics is an Australian clinical-stage oncology company developing small-molecule cancer medicines and modular cell-therapy technologies.
Last updated November 4, 2026
AI crawler reads
3requests
1companies- Anthropic3
- Profile
- 2
- Controversies
- 0
- JSON · MD
- 0
- First read
- Nov 4, 2026
- Latest read
- Nov 4, 2026
From this site's server log
Overview
Prescient Therapeutics Ltd is an Australian clinical-stage biotechnology company focused on oncology. Its development portfolio combines two small-molecule targeted therapies, PTX-100 and PTX-200, with cell-therapy platforms intended to improve the controllability, manufacture, persistence and activity of engineered immune cells. The company is not primarily a commercial pharmaceutical brand: its principal identity is that of a research and development organization whose programs remain dependent on clinical validation, regulatory progress, financing and potential partnerships. The company was assembled in 2014 through a sequence of transactions involving the ASX-listed shell Virax Holdings Ltd and two United States private biotechnology businesses. Virax first acquired Pathway Oncology, the source of PTX-100, in a transaction announced in March 2014 and completed in May. It then acquired AKTivate Therapeutics, which contributed PTX-200, in a transaction announced in October and completed in December. Virax subsequently adopted the Prescient Therapeutics name in December 2014. This structure gave the combined business access to public-market financing while bringing separate oncology assets under one corporate platform. PTX-100 is a targeted small molecule designed to inhibit geranylgeranyl transferase-1, an enzyme involved in the post-translational modification of signaling proteins associated with malignant transformation and cancer-cell survival. Prescient has investigated the compound in hematological and solid malignancies, including T-cell lymphomas. Earlier clinical work reported safety and preliminary activity, and the program progressed to a Phase 1b expansion study in T-cell lymphomas. The United States Food and Drug Administration granted PTX-100 orphan-drug designation for T-cell lymphomas. A later development plan identified a global Phase 2 study in cutaneous T-cell lymphoma as a prospective next step, subject to the usual development and regulatory requirements. PTX-200 is the company's other small-molecule oncology program. It is described as a targeted therapy directed at the AKT signaling pathway, a pathway frequently implicated in cancer-cell growth and survival. The program originated with AKTivate Therapeutics and was incorporated into Prescient's portfolio during the 2014 corporate transactions. Publicly described development information is more limited than for PTX-100, and its clinical status should therefore be distinguished from the more extensively discussed cell-therapy and PTX-100 activities. Prescient broadened its strategy in 2019 by developing CellPryme, a group of technologies intended to improve engineered-cell products. CellPryme-M is designed to influence the phenotype of T cells during manufacture, including the production of cells with characteristics associated with central memory, helper-cell function, chemokine responsiveness and reduced exhaustion. CellPryme-A is an adjunctive treatment intended to modify an immunosuppressive tumor environment when administered with cellular immunotherapy. Preclinical work reported improved tumor trafficking, persistence and antitumor activity in relevant models, but these findings do not establish clinical efficacy in humans. In 2020, Prescient announced OmniCAR, a universal immune-receptor platform developed from technology associated with the University of Pennsylvania and the University of Oxford, combined with Prescient's proprietary work. OmniCAR separates the engineered cell from the targeting binder: binders can be administered, changed, and titrated after cell infusion. The proposed advantages include controllable activation, sequential or simultaneous targeting of multiple antigens, and the possibility of addressing antigen escape and heterogeneity in solid tumors. The platform is initially oriented toward CAR-T oncology applications but may be adaptable to other immune-cell types and to autologous or allogeneic manufacturing models. Prescient's strategy therefore spans conventional targeted drug development and next-generation cellular immunotherapy. Its collaborations with Peter MacCallum Cancer Centre and Q-Gen Cell Therapeutics support platform development and manufacturing, while the company has indicated that its technologies may be used in its own programs or licensed to other cell-therapy developers. As a clinical-stage company, Prescient's future positioning depends on whether its preclinical platform claims translate into safe, reproducible and clinically meaningful therapies.
History
Prescient Therapeutics emerged from the restructuring of Virax Holdings Ltd, an ASX-listed shell company, in 2014. The transaction was organized around two oncology assets held by separate United States private companies. Pathway Oncology owned or controlled the PTX-100 program, while AKTivate Therapeutics contributed PTX-200. Paul Hopper, an Australian biotechnology entrepreneur, helped coordinate the transactions as a way to bring the assets to public markets and finance their further development. Virax announced the acquisition of Pathway Oncology on 17 March 2014 and completed it on 30 May 2014. It then announced the acquisition of AKTivate Therapeutics on 17 October 2014 and completed that transaction on 11 December 2014. After bringing the two businesses and their drug programs together, Virax changed its name to Prescient Therapeutics in December 2014. The new name reflected a shift from the former shell-company identity toward an oncology-focused biotechnology business. PTX-100 became the company's principal small-molecule development program. The compound inhibits geranylgeranyl transferase-1, an enzyme involved in the modification and signaling of proteins in pathways associated with cancer development and cell survival. Prescient describes the mechanism as disrupting signaling through Rho, Rac and Ral circuits and promoting cancer-cell apoptosis. The program was licensed from Yale University and was co-invented by Said Sebti and Andrew Hamilton. A prior Phase 1 study and subsequent pharmacokinetic/pharmacodynamic work provided the basis for continued investigation in both hematological and solid cancers. Prescient later focused a Phase 1b expansion cohort on T-cell lymphomas and reported encouraging early signals alongside a manageable safety profile. PTX-100 also received United States orphan-drug designation for T-cell lymphomas. PTX-200, inherited from AKTivate Therapeutics, is a targeted therapy associated with the AKT cancer-signaling pathway. It remained part of the company's small-molecule oncology portfolio, although the publicly described development record is less extensive than that of PTX-100. Together, the two programs established Prescient's initial identity as a developer of targeted cancer medicines rather than a commercial drug manufacturer. The company expanded into cellular immunotherapy in 2019 with the internal development of CellPryme. Developed with Peter MacCallum Cancer Centre, CellPryme-M is intended to improve the characteristics of cells during manufacturing. Preclinical studies described a greater proportion of central-memory and CD4-positive helper cells, increased chemokine-receptor expression and reduced susceptibility to exhaustion. CellPryme-A was introduced as an intravenous adjunct or neoadjuvant approach intended to reduce suppressive elements in the tumor microenvironment and improve the expansion and penetration of administered CAR-T cells. In May 2020, Prescient introduced OmniCAR, its universal immune-receptor platform. The technology combines a receptor developed from University of Pennsylvania work with the SpyTag/SpyCatcher molecular binding system licensed from the University of Oxford and additional Prescient technologies. Unlike a conventional fixed CAR construct, OmniCAR is designed to separate the cell-signaling component from antigen recognition. A clinician could potentially control activity by dosing the targeting binder after infusion, exchange binders to address different antigens, and repeatedly re-arm the same cell product. Prescient has emphasized possible relevance to solid tumors, where antigen heterogeneity, antigen escape and an immunosuppressive environment create challenges for conventional CAR-T approaches. Following the platform announcement, Prescient reported preclinical findings relating to immunogenicity, dose-responsive tumor killing, repeated arming and sequential redirection. Work involving glioblastoma-associated targets suggested that OmniCAR cells could be redirected from one antigen to another without producing a new cell product. The company also entered a collaboration with Peter MacCallum Cancer Centre to advance the technology. In August 2022, it announced a manufacturing-services agreement with Q-Gen Cell Therapeutics for OmniCAR cell lines intended for its internal clinical programs. Prescient's current identity is consequently built around a portfolio rather than a marketed therapy. It combines PTX-100 and PTX-200 with technologies intended to make cell therapies more controllable, durable and manufacturable. The programs remain subject to clinical, regulatory and commercial uncertainty, and preclinical results should not be treated as proof of human therapeutic benefit.
- 2022
CellPryme-M and CellPryme-A disclosed
[1]Prescient described CellPryme-M as a manufacturing enhancement and CellPryme-A as an adjunct intended to improve the tumor environment for cell therapies.
- 2022
Q-Gen manufacturing agreement announced
[1]Prescient announced manufacturing support from Q-Gen Cell Therapeutics for OmniCAR cell lines.
- 2020
OmniCAR platform announced
[1]Prescient announced its universal immune-receptor platform for controllable and redirectable cellular immunotherapy.
- 2019
CellPryme development begins
[1]Prescient expanded into cell-therapy enhancement through its CellPryme technology work.
- 2014
Pathway Oncology acquisition completed
[1]Virax Holdings completed its acquisition of Pathway Oncology, adding the PTX-100 oncology asset.
- 2014
AKTivate Therapeutics acquisition completed
[1]Virax completed its acquisition of AKTivate Therapeutics, adding PTX-200.
- 2014
Corporate name changed to Prescient Therapeutics
[1]Virax Holdings adopted the Prescient Therapeutics name after consolidating the two oncology businesses.
Products and positioning
A clinical-stage oncology biotechnology company combining targeted small-molecule therapeutics with controllable, modular and manufacturing-focused cell-therapy platforms.
Small-molecule oncology therapy
PTX-100
PTX-100 is a targeted small molecule that inhibits geranylgeranyl transferase-1, an enzyme involved in signaling and protein modification linked to malignant transformation and cancer-cell survival. Prescient has studied it in hematological and solid malignancies, with later development focused on T-cell lymphomas. The program has generated early clinical safety and activity data and received U.S. orphan-drug designation for T-cell lymphomas. It remains an investigational therapy rather than an approved commercial medicine.
Small-molecule oncology therapy
PTX-200
PTX-200 is an investigational targeted oncology compound originating from AKTivate Therapeutics. It is associated with inhibition or modulation of the AKT cancer-signaling pathway, which is implicated in tumor growth and survival. The asset became part of Prescient's portfolio through the 2014 acquisition sequence. Publicly available descriptions provide less current clinical detail than for PTX-100, so its development status should be treated as limited or uncertain.
Universal immune-receptor platform · 2020
OmniCAR
OmniCAR is a modular immune-receptor platform designed to separate antigen recognition from the engineered cell's signaling machinery. Targeting binders can potentially be administered and changed after cell infusion, enabling dose control, repeated re-arming and sequential or simultaneous targeting of multiple antigens. Prescient is initially applying the platform to CAR-T oncology, while describing possible use with other immune-cell types and both autologous and allogeneic approaches. The evidence described publicly is preclinical.
Cell-therapy manufacturing enhancement · 2022
CellPryme-M
CellPryme-M is intended to shape T-cell characteristics during a rapid manufacturing step. Prescient reports that the process can increase central-memory and helper-cell features, chemokine-receptor expression and resistance to exhaustion. In preclinical solid-tumor models, CellPryme-M-enhanced CAR-T cells showed stronger persistence, trafficking and tumor-killing performance than conventional comparators. The technology is intended for Prescient's own programs and potential external licensing.
Cell-therapy adjunct · 2022
CellPryme-A
CellPryme-A is an intravenous adjunct or neoadjuvant technology designed to support cellular immunotherapy in an immunosuppressive tumor microenvironment. In a preclinical HER2-positive colon-carcinoma model, Prescient reported fewer suppressive regulatory T cells, greater CAR-T expansion and improved tumor penetration. Combined use with CellPryme-M produced larger effects in the reported studies. CellPryme-A remains an investigational, preclinical platform.
Brand decisions
2020
Introduce the OmniCAR platformProduct launchBackground
Conventional CAR-T products generally fix antigen recognition within the engineered cell, creating challenges when tumors vary their antigens or become resistant.
Action taken
Prescient combined University of Pennsylvania and Oxford-associated technologies with its own work to create a universal, binder-controlled immune-receptor platform.
Aftermath
The company pursued preclinical studies involving dose control, re-arming and sequential antigen redirection, followed by research and manufacturing collaborations.
2019
Expand from small molecules into cell therapyStrategyBackground
Prescient sought to broaden its oncology pipeline beyond targeted small-molecule drugs.
Action taken
The company began developing CellPryme technologies aimed at improving cell manufacture and the performance of engineered immune cells.
Aftermath
Cell therapy became a central part of the company's platform strategy alongside PTX-100 and PTX-200.
2014
Use reverse takeovers to consolidate oncology assetsM&ABackground
Prescient's predecessor, Virax Holdings, was an ASX-listed shell seeking a public-market structure for two oncology assets held by separate United States private companies.
Action taken
Virax acquired Pathway Oncology and then AKTivate Therapeutics in sequential transactions, bringing PTX-100 and PTX-200 into one listed company.
Aftermath
The company changed its name to Prescient Therapeutics in December 2014 and adopted a consolidated oncology-development strategy.
Recent events
- Unconfirmed
Reported
Prescient acquires Strategic North[2]
Prescient announced that it had acquired Strategic North, a global commercial strategy consultancy. The transaction was described as enhancing services offered to pharmaceutical and biotech clients of both organizations.
- Unconfirmed
Reported
Quilter acquires Prescient[3]
Quilter’s financial planning arm bought national advice firm Prescient. The acquisition added more than £800 million of assets under advice to Quilter PCA.
Sources3 sources
Cite this profile: Cite the canonical profile. /brand-wiki/prescient-therapeutics · Editorial policy · How profiles are compiled